Cargando…

Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types

BACKGROUND: An important step towards personalizing cancer treatment is to integrate heterogeneous evidences to catalog mutational hotspots that are biologically and therapeutically relevant and thus represent where targeted therapy would likely be beneficial. However, existing methods do not suffic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Tenghui, Wang, Zixing, Zhou, Wanding, Chong, Zechen, Meric-Bernstam, Funda, Mills, Gordon B., Chen, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928158/ https://www.ncbi.nlm.nih.gov/pubmed/27356755 http://dx.doi.org/10.1186/s12864-016-2727-x

Ejemplares similares

Cancer driver mutation prediction through Bayesian integration of multi-omic data
por: Wang, Zixing, et al.
Publicado: (2018)

ClinSeK: a targeted variant characterization framework for clinical sequencing
por: Zhou, Wanding, et al.
Publicado: (2015)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations
por: Malhotra, Ankit, et al.
Publicado: (2015)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

novoBreak: local assembly for breakpoint detection in cancer genomes
por: Chong, Zechen, et al.
Publicado: (2016)

Towards accurate characterization of clonal heterogeneity based on structural variation
por: Fan, Xian, et al.
Publicado: (2014)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Sequence and Structure Signatures of Cancer Mutation Hotspots in Protein Kinases
por: Dixit, Anshuman, et al.
Publicado: (2009)

Comparative analysis of Dendrobium plastomes and utility of plastomic mutational hotspots
por: Zhitao, Niu, et al.
Publicado: (2017)

Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions
por: Wong, John K. L., et al.
Publicado: (2022)

Hotspots of Human Mutation
por: Nesta, Alex V., et al.
Publicado: (2020)

Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer
por: Chen, Weiran, et al.
Publicado: (2018)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

A full-proteome, interaction-specific characterization of mutational hotspots across human cancers
por: Chen, Siwei, et al.
Publicado: (2022)

Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures
por: Gouda, Mohamed A, et al.
Publicado: (2022)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations
por: Somaiah, Neeta, et al.
Publicado: (2018)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

An analysis of mutational signatures of synonymous mutations across 15 cancer types
por: Bin, Yannan, et al.
Publicado: (2019)

MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis
por: Jia, Peilin, et al.
Publicado: (2014)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Delineating the expanding phenotype associated with SCAPER gene mutation
por: Fasham, James, et al.
Publicado: (2019)

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
por: Liang, Winnie S., et al.
Publicado: (2018)

Mutation hotspots in cis-regulatory regions in cancer
por: Poulos, Rebecca C., et al.
Publicado: (2016)

TERT promoter hotspot mutations in breast cancer
por: Shimoi, Tatsunori, et al.
Publicado: (2017)

Generation of mutation hotspots in ageing bacterial colonies
por: Sekowska, Agnieszka, et al.
Publicado: (2016)

Characteristics and Mutational Hotspots of Plastomes in Debregeasia (Urticaceae)
por: Wang, Ruo-Nan, et al.
Publicado: (2020)

Hotspot Mutations in SARS-CoV-2
por: Saha, Indrajit, et al.
Publicado: (2021)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer
por: Xing, Rui, et al.
Publicado: (2019)

Delineation of the movement disorders associated with FOXG1 mutations
por: Papandreou, Apostolos, et al.
Publicado: (2016)

Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer
por: Shi, Ming-Jun, et al.
Publicado: (2020)

MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer
por: Gauthier, Nicholas Paul, et al.
Publicado: (2016)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rrjjfh57ds85r36apsamu231br